$2.48T
Total marketcap
$74.88B
Total volume
BTC 50.56%     ETH 15.07%
Dominance

Sorrento Therapeutics, Inc. 0L85.L Stock

0.02 USD {{ price }} -47.391304% {{change_pct}}%
Exchange
LSE
Market Cap
28.28K USD
LOW - HIGH [24H]
0.0000 - 0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.527 USD

Sorrento Therapeutics, Inc. Price Chart

Sorrento Therapeutics, Inc. 0L85.L Financial and Trading Overview

Sorrento Therapeutics, Inc. stock price 0.02 USD
Previous Close 0.36 USD
Open 0 USD
Bid 0 USD x N/A
Ask 0 USD x N/A
Day's Range 0 - 0 USD
52 Week Range 0 - 3.06 USD
Volume 22.4K USD
Avg. Volume 10.41K USD
Market Cap 437.45K USD
Beta (5Y Monthly) 2.099647
PE Ratio (TTM) N/A
EPS (TTM) -1.527 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

0L85.L Valuation Measures

Enterprise Value 313.04M USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.007206128
Price/Book (mrq) N/A
Enterprise Value/Revenue 5.157
Enterprise Value/EBITDA -0.877

Trading Information

Sorrento Therapeutics, Inc. Stock Price History

Beta (5Y Monthly) 2.099647
52-Week Change -78.041%
S&P500 52-Week Change 20.43%
52 Week High 3.06 USD
52 Week Low 0 USD
50-Day Moving Average 0.31 USD
200-Day Moving Average 1.2 USD

0L85.L Share Statistics

Avg. Volume (3 month) 10.41K USD
Avg. Daily Volume (10-Days) 2.93K USD
Shares Outstanding 111.3M
Float 538.99M
Short Ratio N/A
% Held by Insiders 0.89%
% Held by Institutions 29.37%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -610.55%
Gross Margin -285.36%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -35.21%
Return on Equity (ttm) -1400.80%

Income Statement

Revenue (ttm) 60.71M USD
Revenue Per Share (ttm) 0.13 USD
Quarterly Revenue Growth (yoy) -11.60%
Gross Profit (ttm) -191839000 USD
EBITDA -357067008 USD
Net Income Avi to Common (ttm) -671644032 USD
Diluted EPS (ttm) -1.527
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 50.32M USD
Total Cash Per Share (mrq) 0.09 USD
Total Debt (mrq) 169.55M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 0.439
Book Value Per Share (mrq) -0.231

Cash Flow Statement

Operating Cash Flow (ttm) -259956000 USD
Levered Free Cash Flow (ttm) -122783752 USD

Profile of Sorrento Therapeutics, Inc.

Country United Kingdom
State CA
City San Diego
Address 4955 Directors Place
ZIP 92121
Phone 858 203 4100
Website https://www.sorrentotherapeutics.com
Industry
Sector(s)
Full Time Employees 949

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Q&A For Sorrento Therapeutics, Inc. Stock

What is a current 0L85.L stock price?

Sorrento Therapeutics, Inc. 0L85.L stock price today per share is 0.02 USD.

How to purchase Sorrento Therapeutics, Inc. stock?

You can buy 0L85.L shares on the LSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Sorrento Therapeutics, Inc.?

The stock symbol or ticker of Sorrento Therapeutics, Inc. is 0L85.L.

How many shares does Sorrento Therapeutics, Inc. have in circulation?

The max supply of Sorrento Therapeutics, Inc. shares is 1.17M.

What is Sorrento Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?

Sorrento Therapeutics, Inc. PE Ratio is now.

What was Sorrento Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?

Sorrento Therapeutics, Inc. EPS is -1.527 USD over the trailing 12 months.